Key result
MitraClip achieves similar procedural success and 6-month MR reduction in noncentral versus central degenerative MR.
Why the study?
It was unknown whether MitraClip therapy in noncentral degenerative mitral regurgitation is as safe and effective as in central degenerative mitral regurgitation.
Does percutaneous edge-to-edge repair with MitraClip achieve similar clinical and echocardiographic outcomes in patients with noncentral degenerative mitral regurgitation compared with central degenerative mitral regurgitation?
Observational (n=79)
Yes
Does percutaneous edge-to-edge repair with MitraClip achieve similar clinical and echocardiographic outcomes in patients with noncentral degenerative mitral regurgitation compared with central degenerative mitral regurgitation?
Percutaneous edge-to-edge repair with MitraClip can be performed safely and with comparable echocardiographic and clinical efficacy in patients with noncentral degenerative mitral regurgitation as in those with central lesions.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our results mean that patients who once had no treatment option can now be treated, with the subsequent improvements in symptoms and life quality,”
MitraClip in noncentral dMR appears feasible; leaves open need for randomized confirmation of safety and durability.
Objectives This study aimed to assess the clinical and echocardiographic results of MitraClip implantation in noncentral degenerative mitral regurgitation (dMR) compared with central dMR. Background It is unknown whether the use of MitraClip therapy in noncentral dMR is as safe and effective as in central dMR. Methods We analyzed a multicenter registry of 173 patients treated with the MitraClip and compared results of central and noncentral dMR. Results Seventy-nine patients (age 79.2 ± 8.0 years, 58.2% men) had dMR. Forty-nine patients (62%) had central dMR, with the remainder classified as noncentral dMR (n = 30, 38%). Patients with noncentral dMR had a wider pre-procedural vena contracta (8.5 ± 2.0 mm vs. 6.9 ± 2.2 mm, p = 0.039) and higher systolic pulmonary pressure (57.9 ± 18.0 vs. 47.3 ± 13.0 mm Hg, p = 0.019). Procedural success was the same in both groups (95.5% central vs. 96.7% noncentral, p = 0.866). Post-procedural MR and New York Heart Association (NYHA) functional class at 1 month (MR ≤2, 96.0% vs. 96.6%, p = 0.866, and NYHA functional class ≤II, 81.6% vs. 90.0%, p = 0.335) and 6 months (95.2% central vs. 91.7% noncentral, p = 0.679; and NYHA functional class >II, 21.1% vs. 0%, p = 0.128) did not differ between groups. There were also no differences in serious post-procedural adverse events: partial clip detachment (central n = 1 [2.0%] vs. noncentral n = 1 [3.3%], p = 1.000), death (5.4% central vs. 13.0% noncentral, p = 0.298), or heart failure admission (10.8% central vs. 8.7% noncentral, p = 0.791). Conclusions In experienced centers, MitraClip treatment can be performed safely and effectively in both central and noncentral dMR.
No takes yet. Share an insight, caveat, or question.
Estévez‐Loureiro et al. (2013) conducted an observational in Degenerative mitral regurgitation (n=79). MitraClip in noncentral degenerative mitral regurgitation vs. MitraClip in central degenerative mitral regurgitation was evaluated on Procedural success (p=0.866). MitraClip in noncentral vs central degenerative MR had similar procedural success (96.7% vs 95.5%, p=0.866) and 6-month MR <=2+ rates (91.7% vs 95.2%, p=0.679).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: